Hemangioblastoma
Symptoms, Doctors, Treatments, Advances & More

Hemangioblastoma Overview

Save information for later
Sign Up

Learn About Hemangioblastoma

View Main Condition: Brain Tumor

What is the definition of Hemangioblastoma?
A Hemangioblastoma is a benign, highly vascular tumor that can occur in the brain, spinal cord, and retina (the light-sensitive tissue that lines the back of the eye). This tumor accounts for about 2% of brain tumors. As it enlarges, it presses on the brain and can cause neurological symptoms, such as headaches, weakness, sensory loss, balance and coordination problems, and/or hydrocephalus (a buildup of spinal fluid in the brain). Most Hemangioblastomas occur sporadically. However, some people develop Hemangioblastomas as part of a genetic syndrome called von Hippel-Lindau syndrome. These people usually develop multiple tumors within the brain and spinal cord over their lifetime.
What are the alternative names for Hemangioblastoma?
  • Hemangioblastoma
Who are the top Hemangioblastoma Local Doctors?
Elite in Hemangioblastoma
Dr. Vivek K. Narayan
Oncology
Elite in Hemangioblastoma
Dr. Vivek K. Narayan
Oncology

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vivek Narayan is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Narayan is rated as an Elite provider by MediFind in the treatment of Hemangioblastoma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Hemangioblastoma, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, and Prostatectomy. Dr. Narayan is currently accepting new patients.

Elite in Hemangioblastoma
Dr. Steven Chang
Neurosurgery | General Surgery
Elite in Hemangioblastoma
Dr. Steven Chang
Neurosurgery | General Surgery

Stanford Health Care

500 Pasteur Dr, 
Palo Alto, CA 
650-497-3306
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Chang is a Neurosurgery specialist and a General Surgeon practicing medicine in Palo Alto, California. Dr. Chang is rated as an Elite provider by MediFind in the treatment of Hemangioblastoma. He is also highly rated in 90 other conditions, according to our data. His clinical expertise encompasses Meningioma, Arteriovenous Malformation, Trigeminal Neuralgia, Awake Craniotomy, and Gamma Knife Radiosurgery.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hemangioblastoma
Dr. Russell Lonser
Neurosurgery
Elite in Hemangioblastoma
Dr. Russell Lonser
Neurosurgery

Ohio State University Hospital-Pavilion

300 W 10th Ave, 
Columbus, OH 
614-366-7744
Languages Spoken:
English
See accepted insurances

Russell Lonser is a Neurosurgery provider practicing medicine in Columbus, Ohio. Dr. Lonser is rated as an Elite provider by MediFind in the treatment of Hemangioblastoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Hemangioblastoma, Von Hippel-Lindau (VHL) Syndrome, Hemangioma, Awake Craniotomy, and Craniectomy.

View All Doctors
What are the latest Hemangioblastoma Clinical Trials?
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Other

Summary: Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO cl...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center